.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average follow-up of 11 months, clients along with metastatic stomach cysts who acquired biomarker-matched therapies based upon circulating cyst DNA profiling presented a better medical perk than those obtaining unequaled treatment.